Ammar Qadan

RxScorecard lets a biopharma company anticipate the most important factors impacting the clinical & economic value of pipeline and marketed drugs — and then helps identify the necessary changes to the clinical development and commercial program to maximize that value for all stakeholders, especially including payers. It’s a required, straightforward, objective strategic tool that allows us to quickly and effectively adapt to a rapidly changing and much more challenging market access environment.